25/06/2026 09:21

ResMed Inc (ASX: RMD) $27.93

Global leader in sleep apnoea RMD delivered a solid result in March here, and importantly hasn’t delivered any downgrades. However, the stocks still fallen ~40% over the last year being caught up in the SaaSocalypse, the one part of its business that’s struggled to meet expectations.

Read more

01/05/2026 16:54

ResMed Inc (ASX:RMD) 28.73

RMD -3.53%:  ResMed delivered a solid March quarter result, with revenue and earnings both ahead of expectations, helped by ongoing demand for its sleep apnoea devices, masks and broader connected-care ecosystem. 

Read more

23/04/2026 09:18

ResMed Inc. (ASX:RMD) $30.76

ResMed is a $45bn global medical technology leader focused on sleep apnea and respiratory care, and the clear market leader in sleep-disordered breathing. Its core business centres on CPAP devices and masks, increasingly cloud-connected to improve outcomes and reduce healthcare costs, while a growing SaaS division (e.g. Brightree, MatrixCare) expands its exposure to home-based care. Operating in 140+ countries, ResMed sits at the centre of the shift toward digital and at-home healthcare.

Read more

04/02/2026 09:26

ResMed Inc (RMD) $36.29

It’s not just the software stocks that have struggled in FY26; the healthcare sector is not too far behind - over the last 6-months the ASX tech sector has fallen 34%, with healthcare 24%. Two previously adored sectors are dominating the losers' enclosure.

Read more

03/02/2026 09:30

ResMed Inc (RMD) $37.06

RMD's recent earnings saw a few upgrades to the stock, but the gains were short-lived, and it has drifted back towards its multi-month lows. However, we like the narrative unfolding at RMD with Ozempic-style drugs actually increasing demand for sleep devices as consumers become more focused on their health, with wearable devices such as smartwatches highlighting sleep apnoea and sleep quality in general.

Read more

04/11/2025 09:24

ResMed Inc (RMD) $37.83

RMD retreated 4.3% on Monday, its largest decline since April, after the sleep apnoea business reported 1Q results. The main issue was that organic growth slowed, marking the 3rd consecutive quarter of slowing organic growth rates.

Read more

29/10/2025 09:39

ResMed Inc (RMD) $39.29

RMD remains a global leader in sleep and respiratory care, offering CPAP devices, masks, and digital health software that treat sleep apnoea and chronic respiratory disorders.

Read more

16/09/2025 09:43

ResMed Inc (RMD) $40.68

RMD has drifted 10% in recent weeks, taking its direction from a lacklustre healthcare sector. The stock rallied into and through its fourth quarter FY25 earnings on July 31st but its struggled since, taking little solace from a strong market.

Read more

07/03/2025 09:22

ResMed Inc (RMD) $35.65

Sleep disorder business RMD fell 3.4% on Thursday, making it the standout loser in the healthcare sector after founder Peter Farrell sold $500k worth of shares.

Read more

13/02/2025 09:28

ResMed Inc (RMD) $37.55

Sleep disorder business RMD has slipped from all-time highs after reporting its quarterly results last week. The weakening trend in organic sales overshadowed the strong financial performance. This remains an impressive business, but after recovering strongly from Ozempic worries in 2024, we must consider what is next.

Read more